MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 11..19 of 19 - per page Previous page
Order by
This TACE inhibitory protein could be used as a new therapeutic agent against chronic inflammatory diseases that are mediated by TNF-alpha. More
New pharmaceutical compositions for oral use containing diclofenac together with alkali metal carbonates and bicarbonates and particular flavouring substances. More
The use of vitamin-drug formulations to (a) enable oral absorption of pharmaceutically active ingredients which are not normally absorbed in the GI tract and (b) enhance delivery of drugs to diseases such as cancer and rheumatoid arthritis. More
The primary function of ADAMTS-2 is the maturation of procollagen type I, II and III. Results obtained by in vitro testing, ex vivo model, and in vivo model support the hypothesis that ADAMTS-2 is an anti-angiogenic factor. More
Angiogenesis, cancer, diabetic retinopathy, tilted peptide More
This invention relates to methods for manipulating the immune system using small interfering RNA (siRNA). Potential applications include the development of organ storage/reperfusion solutions and treatments for a broad range of disease indications. More
This invention concerns a new approach to the treatment of rheumatoid arthritis (RA) by "tolerogenic vaccination" with small interfering RNA (siRNA) technology. More
Specific therapeutic target on platelets for blocking inflammatory diseases of the joint: “collagen microparticle footprint” More
Name of the primary inventor: Jeremy Mao. Invention: Composition and methods for replacement of synovial joints. Unmet Need: Synovial joints are susceptible to osteoarthritis (OA), rheumatoid arthritis (RA), trauma, and congenital anomalies. An estimated. More
Displaying 11..19 of 19 - per page Previous page
Order by

Your selection

Therapeutic target
Musculoskeletal del
Skeletal del
Rheumatoid arthritis del

Browse By

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us